Dianthus Therapeutics DNTH License — Revenue
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Dianthus Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Dianthus Therapeutics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Dianthus Therapeutics's license — revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Dianthus Therapeutics's license — revenue?
- Dianthus Therapeutics (DNTH) reported license — revenue of $463K in Q1 2026.
- How has Dianthus Therapeutics's license — revenue changed year-over-year?
- Dianthus Therapeutics's license — revenue decreased by 60.2% year-over-year, from $1.16M to $463K.
- What does license — revenue mean?
- This metric represents the total gross revenue recognized from licensing agreements or intellectual property arrangements within a specific business segment, excluding any pass-through taxes. It reflects the company's ability to monetize its proprietary technology or research assets through partnerships or commercial collaborations. Growth in this figure indicates successful commercialization of the company's pipeline and the strength of its intellectual property portfolio.